• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CLADRIBINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CLADRIBINE chembl:CHEMBL1619 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    LEUSTAT
    CLADRIBINE
    LITAK
    CLADARIBINE
    LEUSTATIN
    NSC-105014
    RWJ-26251
    NSC-105014-F
    MAVENCLAD
    NSC-05014
    2-CHLORO-2'-DEOXY-BETA-ADENOSINE
    CLADRIBINUM
    CLADRIBINA
    CLDADO
    2CLADO
    2-CHLORO-DEOXYADENOSINE
    2-CDA
    2-CHLORODEOXYADENOSINE
    2-CHLORO-6-AMINO-9-(2-DEOXY-BETA-D-ERYTHRO-PENTOFURANOSYL)PURINE
    (2R,3S,5R)-5-(6-AMINO-2-CHLOROPURIN-9-YL)-2-(HYDROXYMETHYL)OXOLAN-3-OL
    2-CHLORO-2'-DEOXYADENOSINE
    pubchem.compound:20279
    chemidplus:4291-63-8
    drugbank:00242
    chembl:CHEMBL1619
    rxcui:44157

    Drug Info:

    (2 More Sources)

    Publications:

    Sampat et al., 2009, Clofarabine: emerging role in leukemias., Expert Opin Investig Drugs
    Kantarjian et al., 2007, Clofarabine: past, present, and future., Leuk. Lymphoma
    Zhenchuk et al., 2009, Mechanisms of anti-cancer action and pharmacology of clofarabine., Biochem. Pharmacol.
    Takahashi et al., 1999, Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration., Cancer Chemother. Pharmacol.
    Kline et al., 2005, Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review., Expert Opin Pharmacother
    Cao X et al., 2013, RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients., Pharmacogenomics
    Chow et al., 2003, Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation., Biochem. Pharmacol.
    Duechler et al., 2005, In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells., Eur. J. Haematol.
    Liu et al., 1998, Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study., Cancer Lett.
    Galmarini et al., 2003, Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine., Biochem. Pharmacol.
    Gora-Tybor et al., 2002, Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia., Neoplasma
    Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics
    Sabini et al., 2008, Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase., J. Med. Chem.
  • CLADRIBINE   RRM2B

    Interaction Score: 3.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19715446 17852710 19576186 9923554 16316309 24024897


    Sources:
    PharmGKB

  • CLADRIBINE   NT5C1A

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26906009


    Sources:
    PharmGKB

  • CLADRIBINE   RRM2

    Interaction Score: 2.4

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19715446 17852710 19576186 9923554 16316309 24024897


    Sources:
    PharmGKB

  • CLADRIBINE   DIABLO

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12948851


    Sources:
    NCI

  • CLADRIBINE   BCL2L2

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15813915


    Sources:
    NCI

  • CLADRIBINE   RRM1

    Interaction Score: 2.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19715446 17852710 19576186 9923554 16316309 24024897


    Sources:
    PharmGKB

  • CLADRIBINE   DCK

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18570408


    Sources:
    NCI

  • CLADRIBINE   XIAP

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12948851 15813915


    Sources:
    NCI

  • CLADRIBINE   CDKN1A

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12473386


    Sources:
    NCI

  • CLADRIBINE   ADA

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CLADRIBINE   IL2RA

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9619876


    Sources:
    NCI

  • CLADRIBINE   TGFB1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12097998


    Sources:
    NCI

  • CLADRIBINE   YES1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLADRIBINE   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CLADRIBINE   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: 2-CDA

    • Version: 14-September-2017

    Alternate Names:
    C1336 NCI drug code

    Drug Info:

    Publications:
    Duechler et al., 2005, In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells., Eur. J. Haematol.
    Liu et al., 1998, Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study., Cancer Lett.
    Galmarini et al., 2003, Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine., Biochem. Pharmacol.

  • NCI: CLADRIBINE

    • Version: 14-September-2017

    Alternate Names:
    C1336 NCI drug code

    Drug Info:

    Publications:
    Sabini et al., 2008, Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase., J. Med. Chem.
    Chow et al., 2003, Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation., Biochem. Pharmacol.

  • PharmGKB: cladribine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cao X et al., 2013, RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients., Pharmacogenomics
    Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics

  • DTC: CLADRIBINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1619 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Cladribine

    • Version: 2020.06.01

    Alternate Names:
    D05GJW TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1619

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21